News and Announcements
OpenDNA to Partner with Miramar
- Published August 22, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Almost 74% of online consumers become frustrated with websites when content is not personalised or related to their interests. The reality of customer engagement today is that the more personalised the better the experience and rewards for the businesses that are adopting Artificial Intelligence (AI).
KEY TAKEAWAYS:
- The power of AI lies in its ability to collect large volumes of data in real-time, recognise patterns and behaviours, learn from them and enable better decision making.
- Miramar has recently partnered up with OpenDNA to offer businesses the ability to better understand their customers to help drive personalised and relevant experiences for their users.
“Miramar, a leading Executive Search firm, are working with businesses in industries like manufacturing, TMT, energy and life sciences to define and shape their digital strategy to enable them to stay ahead of their competition. This begins with building passionate teams that are aligned on the vision and strategy of their digital transformation to ultimately deliver a platform for a more focused, personalised engagement with consumers.”
OpenDNA is the world’s most advanced AI platform for Business. It enables the understanding of an end-user down to an individual level and can drive better customer engagement, retention and conversion through the use of psychographic profiling technology.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
